CAMBRIDGE, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of its conference call at 8:30 a.m. ET on Thursday, October 27, 2005. Dr. Deborah Dunsire, chief executive officer, will host the call. Senior management will discuss the Company’s third quarter 2005 financial results and additional corporate activities. The Company will announce its financial results for this period in a press release to be issued after market close on Wednesday, October 26, 2005.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The press release and the live webcast can be accessed by visiting the Investors section of the Company’s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com.
Contact: Kyle Kuvalanka Theresa McNeely Investor Relations Media Relations (617) 761-4734 (617) 761-6996
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Kyle Kuvalanka, Investor Relations, +1-617-761-4734, or TheresaMcNeely, Media Relations, +1-617-761-6996, both of MillenniumPharmaceuticals, Inc.
Web site: http://www.millennium.com//
Company News On-Call: http://www.prnewswire.com/comp/114562.html /
